Estimates used to calculate the effect of thrombophilia testing for patients with VTE
| . | Prevalence, median % (min-max) . | RR for VTE recurrence, positive vs negative (95% CI) . | Treatment effect for VTE recurrence, RR (95% CI) . | Treatment effect major bleeding, RR (95% CI) . |
|---|---|---|---|---|
| Any thrombophilia | 38.0 (21.6-59.5) | 1.65 (1.28-2.47) | 0.15 (0.10-0.23) | 2.17 (1.40-3.35) |
| FVL homozygous | 1.5 (0.3-3.1) | 2.10 (1.09-4.06) | ||
| FVL heterozygous | 17.5 (4.1-34.8) | 1.36 (1.19-1.57) | ||
| PGM | 6.1 (1.4-16.3) | 1.34 (1.05-1.71) | ||
| Antithrombin (AT) deficiency | 2.2 (0.2-8.7) | 2.07 (1.50-2.87) | ||
| Protein C (PC) deficiency | 2.5 (0.7-8.6) | 2.13 (1.26-3.59) | ||
| Protein S (PS) deficiency | 2.3 (0.7-7.3) | 1.30 (0.87-1.94) | ||
| AT, PC, or PS deficiency | 7.0 (2.5-18.4) | 1.62 (1.17-2.23) | ||
| APLA | 9.7 (1.9-19.4) | 1.92 (0.99-3.72) |
| . | Prevalence, median % (min-max) . | RR for VTE recurrence, positive vs negative (95% CI) . | Treatment effect for VTE recurrence, RR (95% CI) . | Treatment effect major bleeding, RR (95% CI) . |
|---|---|---|---|---|
| Any thrombophilia | 38.0 (21.6-59.5) | 1.65 (1.28-2.47) | 0.15 (0.10-0.23) | 2.17 (1.40-3.35) |
| FVL homozygous | 1.5 (0.3-3.1) | 2.10 (1.09-4.06) | ||
| FVL heterozygous | 17.5 (4.1-34.8) | 1.36 (1.19-1.57) | ||
| PGM | 6.1 (1.4-16.3) | 1.34 (1.05-1.71) | ||
| Antithrombin (AT) deficiency | 2.2 (0.2-8.7) | 2.07 (1.50-2.87) | ||
| Protein C (PC) deficiency | 2.5 (0.7-8.6) | 2.13 (1.26-3.59) | ||
| Protein S (PS) deficiency | 2.3 (0.7-7.3) | 1.30 (0.87-1.94) | ||
| AT, PC, or PS deficiency | 7.0 (2.5-18.4) | 1.62 (1.17-2.23) | ||
| APLA | 9.7 (1.9-19.4) | 1.92 (0.99-3.72) |
APLA, antiphospholipid antibody (including lupus anticoagulant).